RARE Stock Drops 46% After Angelman Syndrome Drug Trial Fails
Ultragenyx Pharmaceutical (RARE) stock plunged 46% in after-hours trading Wednesday after the company announced its experimental Angelman syndrome drug apazunersen failed a late-stage clinical trial. The stock closed regular trading at $26.53 before sliding into the mid-teens after hours. The late-s
LucasBennett·09-02 22:50
